Novel autoantibodies in rheumatoid arthritis

Submitted: 28 November 2017
Accepted: 6 September 2018
Published: 1 April 2019
Abstract Views: 2205
PDF: 1520
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Rheumatoid factor and antibodies against cyclic citrullinated peptides represent a diagnostic hallmark in rheumatoid arthritis (RA). However, over the last decades many other autoantibodies have been identified. Several proteins can trigger an aberrant autoimmune response in their native form while others acquire this feature after post-translational modifications such as citrullination, carbamylation or acetylation. It is of interest that also the enzymes catalyzing such post-translational modifications (e.g. the protein arginine deiminases) can transform themselves into autoantibodies in RA. The purpose of this review article is to provide an overview of relevant literature published over the last years regarding novel autoantibodies and their possible diagnostic and prognostic significance in RA.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Bonifacio, A., Alunno, A., La Paglia, G., Valentini, E., Leone, M., Bartoloni, E., & Gerli, R. (2019). Novel autoantibodies in rheumatoid arthritis. Reumatismo, 71(1), 1–12. https://doi.org/10.4081/reumatismo.2019.1102